Depiction of Prostate Cancer Treatment Alternatives in Greece

This study has been completed.

First Received: August 8, 2008 Last Updated: March 9, 2009 History of Changes

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00733213

Purpose

A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the Greek clinical practice.

Target Group: Patients with locally advanced or metastatic prostate cancer.
The first 10 consecutive patients records that meet the entry criteria.

Condition
Locally Advanced or Metastatic Prostate Cancer.

MedlinePlus related topics: Cancer Prostate Cancer

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Retrospective
Official Title:	Depiction of Prostate Cancer Treatment Alternatives in Greece

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Percentage of patients treated by each treatment alternative. [ Time Frame: Between 2002 - 2008 ]

Secondary Outcome Measures:

To depict sociodemographic characteristics and comorbidities. [ Time Frame: Between 2002 - 2008 ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	310
Study Start Date:	January 2008
Study Completion Date:	March 2009

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Study Population

Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer

Criteria

Inclusion Criteria:

Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002.
Patients that received Hormonal therapy.

Exclusion Criteria:

Males that are aged less than 18 years

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00733213

Locations

Greece
Research Site
Athens, Greece
Research Site
Karditsa, Greece
Research Site
Serres, Greece
Research Site
Xsanthi, Greece

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Panagiotis Pontikis, MD

AstraZeneca Greece

More Information

No publications provided

Responsible Party:	AstraZeneca, SA Greece ( Dr Pontikis Panagiotis, MD Medical and Regulatory Affairs Director )
Study ID Numbers:	NIS-OGR-DUM-2007/1
Study First Received:	August 8, 2008
Last Updated:	March 9, 2009
ClinicalTrials.gov Identifier:	NCT00733213 History of Changes
Health Authority:	Greece: National Organization of Medicines

Keywords provided by AstraZeneca:

Prostate Cancer, Treatment alternatives, Metastasis

Study placed in the following topic categories:

Prostatic Diseases
Genital Neoplasms, Male
Neoplasm Metastasis

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male

Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on May 07, 2009